RemeGen Announces US FDA Has Granted Breakthrough Therapy Designation for Disitamab Vedotin (RC48) in Urothelial Cancer
RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
荣昌生物正式入驻北京中海广场
荣昌生物房健民:做特立独行的ADC,找准适应症不扎堆
泰它西普:全球原创新药从烟台走向世界
【山东新闻联播】荣昌生物:新药产业化撬动生物医药产业集群